Endovascular Repair Using the Talent™ Abdominal Stent Graft System in Abdominal Aortic Aneurysms (VITALITY)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 94
- 试验地点
- 36
- 主要终点
- Freedom From Aneurysm-related Mortality (ARM)
研究概览
简要总结
The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.
详细描述
The Talent Abdominal Stent Graft System is a next-generation modular system for endovascular repair of Abdominal Aortic Aneurysm (AAA). The system was designed with the following enhancements: a suprarenal wire frame to provide migration resistance, and improved flexibility designed to treat difficult anatomies.
Medtronic Vascular submitted a Pre-Market Application (PMA) to the Food and Drug Administration (FDA) on October 17, 2007, and received market approval for the Talent Abdominal Stent Graft System on April 15th, 2008. As a condition of approval, the FDA has requested a post-approval study. Medtronic has therefore designed a post-approval study, in collaboration with FDA, to document the performance of the Talent Abdominal Stent Graft System under market conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must have an abdominal aortic aneurysm, with or without iliac involvement.
- •Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
- •A proximal aortic neck length of ≥ 10mm;
- •Proximal aortic neck angulation ≤ 60°;
- •Distal iliac artery fixation length of ≥ 15mm;
- •An aortic neck diameter of 18-32mm and iliac artery diameters of 8-22mm; and
- •Vessel morphology suitable for endovascular repair.
排除标准
- •Are less than 18 years of age
- •Are pregnant or lactating
- •Have a dominant patent inferior mesenteric artery and an occluded or stenotic celiac and/or superior mesenteric artery
- •Have aneurysmal involvement or occlusion (surgically performed or naturally occurring) of the bilateral internal iliac arteries
- •Have vessels and/or aneurysm dimensions that cannot accommodate the Talent Abdominal Stent Graft as per the indications in Section
- •Have no distal vascular bed (one vessel lower extremity run-off required)
- •Have contraindications for use of contrast medium or anticoagulation drugs
- •Have an uncorrectable coagulopathy
- •Have an SVS/AAVS score greater than 2
- •Have a mycotic aneurysm
- •Have circumferential mural thrombus in the proximal aortic neck
- •Have had a recent (within 3 months) myocardial infarction (MI), cerebral vascular accident (CVA), or major surgical intervention
- •Have traumatic aortic injury
- •Have leaking, pending rupture or ruptured aneurysms
- •Have pseudoaneurysms resulting from previous graft placement
- •Require a revision to previously placed endovascular stent grafts.
- •Have genetic connective tissue disease (e.g., Marfan's or Ehlers-Danlos' Syndromes)
- •Have concomitant thoracic aortic or thoracoabdominal aneurysms
- •Are patients with active systemic infections
- •Are patients who have a condition that threatens to infect the graft.
- •Are patients with sensitivities or allergies to the device materials.
- •Have access vessels (as determined by treating physician) that preclude safe insertion of the delivery system. NOTE: Iliac conduits may be used to ensure the safe insertion of the delivery system.
结局指标
主要结局
Freedom From Aneurysm-related Mortality (ARM)
时间窗: 5 year Kaplan Meier (KM)
ARM is defined as death from rupture of the abdominal aortic aneurysm or from any procedure intended to treat the Abdominal Aortic Aneurysm (AAA). If a death occurred within 30 days of any procedure intended to treat the AAA, then it is presumed to be aneurysm related unless there is evidence to the contrary. Deaths occurring after 30 days of any procedure intended to treat the AAA that are procedure-related should also be aneurysm related. All deaths were adjudicated by a Clinical Events Committee (CEC) to determine aneurysm, device and/or procedure relatedness.
次要结局
未报告次要终点